Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.
Kozák
T
T
Department of Clinical Haematology, Prague, Czech Republic. kozak@bon.cz
Havrdová
E
E
Pit'ha
J
J
Gregora
E
E
Pytlík
R
R
Maaloufová
J
J
Kobylka
P
P
Vodvárková
S
S
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D008279:Magnetic Resonance Imaging; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D018579:Patient Selection; D013601:T-Lymphocytes / Q000276:immunology
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine